NEW YORK (GenomeWeb News) – Regulus Therapeutics, a developer of microRNA-based therapeutics, announced after the close of the market Wednesday that it has signed a deal with Biogen Idec to identify blood-borne miRNA biomarkers for multiple sclerosis.

In exchange for its miRNA know how, Regulus will receive undisclosed upfront and milestone payments. Biogen Idec will also make an undisclosed investment in Regulus, which was formed in 2007 as a joint venture between RNAi firm Alnylam Pharmaceuticals and antisense drug developer Isis Pharmaceuticals.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.